Travere Therapeutics, based in San Diego, focuses on developing therapies for rare kidney and metabolic diseases, with products like FILSPARI for IgAN and Pegtibatinase for classical homocystinuria. Founded in 2003, the company employs 380 people and also offers Thiola for cystinuria.
Roy D Baynes sold 10,000 shares of TVTX on 6 February at $22.00 per share, worth a total of $220K. They now own 31,000 TVTX shares, or a 24% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
